UNSPSC 51381506: Morniflumate

This classification denotes an anti-infective agent with the molecular formula C19H20F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R133MWH7X1, chemically known as 3-pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)-, 2-(4-morpholinylethyl) ester but generally known as morniflumate, which bears US NIH Compound Identifier 72106. European Medicines Agency schedules Morniflumate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09068MIG.

UNSPSC 51381506 Morniflumate is a Commodity code under which state and local governments procure pharmaceutical products, though recent solicitations show activity concentrated in naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through established wholesaler networks and direct-to-manufacturer prescription programs. State and local issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of participating government facilities. Procurement is driven by public health and community health initiatives, with vendors required to meet cGMP certification, Drug Supply Chain Security Act compliance, and FDA requirements, including expiration-date standards with minimum six-month shelf life. Contracts typically carry insurance requirements (commercial general liability in the range of $2 million to $5 million per occurrence, workers' compensation, and professional liability), E-Verify compliance, and drug-free workplace certification.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023 — note the inconsistent date in source documentation) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, under a two-year initial term with one-year renewal option, potentially funded through FEMA. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capability for direct contracting with self-insured plans outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, requiring vendors to work through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) with awards effective July 1, 2026. The MMCAP solicitation weights price competitiveness at seventy-five percent and requires vendors to maintain relationships with at least two of three authorized wholesalers with chargeback systems in place.